← FDA DRUG APPROVALS

FDA ANDA · ANDA206084

LYPQOZET

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA206084
TYPE
ANDA
ORIGINAL APPROVAL
2017-04-26
LATEST ACTION
2021-02-16
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LYPQOZETPrescription
ATORVASTATIN CALCIUM EQ 40MG BASE, EZETIMIBE 10MG · TABLET · ORAL
LYPQOZETPrescription
ATORVASTATIN CALCIUM EQ 10MG BASE, EZETIMIBE 10MG · TABLET · ORAL
LYPQOZETPrescription
ATORVASTATIN CALCIUM EQ 80MG BASE, EZETIMIBE 10MG · TABLET · ORAL
LYPQOZETPrescription
ATORVASTATIN CALCIUM EQ 20MG BASE, EZETIMIBE 10MG · TABLET · ORAL

Approval history

2021-02-16Labeling · Supplement 2 · standardAP
2021-01-15Labeling · Supplement 3 · standardAP
2021-01-13Labeling · Supplement 4 · standardAP
2021-01-13Labeling · Supplement 5 · standardAP
2021-01-13Labeling · Supplement 1 · standardAP
2017-04-26UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →